GlassScriptPhysician profile
James S Amontree
NPI 1235117730
$2,728.76
in general payments reported to CMS, 2019-2025
23 companies · $645 in 2025
The $645 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $111 · 2021: $447 · 2022: $228 · 2023: $374 · 2024: $696 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.87 | 2019-2025 | Rinvoq, Skyrizi |
| Boston Scientific Corporation | $337.26 | 2019-2025 | Watchman Flx, Ams 700 |
| Braintree Laboratories, INC. | $271.80 | 2020-2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $264.13 | 2021-2023 | Epclusa |
| Medtronic, INC. | $236.70 | 2024-2025 | Interstim |
| Pfizer INC. | $198.98 | 2019-2025 | |
| Janssen Biotech, INC. | $196.24 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $134.51 | 2021-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $122.63 | 2019-2024 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $97.38 | 2023-2025 | Fujifilm |
| Nestle Healthcare Nutrition INC. | $97.26 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $53.74 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $46.85 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $46.66 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $41.87 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $34.91 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $34.44 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $31.72 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $21.73 | 2025 | Givlaari |
| Organon LLC | $18.61 | 2024 | |
| Ironwood Pharmaceuticals, INC | $17.29 | 2022 | |
| Redhill Biopharma INC. | $14.93 | 2021 | |
| Biodelivery Sciences International, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Amontree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.